CGRP antagonists
FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients
One in ten children and adolescents in the US are affected by the neurological condition
Rain Free Days: A Migraine App Shaped by Real Experiences
Rain Free Days® is a free migraine support app created by Teva, 11 London, and the migraine community. It helps users track symptoms, spot patterns, and access personalised resources like...
FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar
Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease
Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired
Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined
Nearly 500,000 died from an opioid overdose between 1999 and 2019
Pfizer to acquire Biohaven in deal worth over $11bn
The deal will expand Pfizer’s Internal Medicine pipeline
Teva reaches $925,000 settlement to resolve drug price-fixing claims
Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe
Pfizer, Sanofi and others set to increase US drug prices in 2021
Pressure from COVID-19 restrictions leads to drug price increases
US charges Teva for generic drug price-fixing plot
Company maintains it has not committed any wrongdoing
Biohaven gets FDA approval for migraine drug Nurtec ODT
Becomes second drugmaker to bring an oral CGRP inhibitor to US market